Published in BMC Med on July 23, 2013
Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacol Sin (2015) 0.99
Self-folding single cell grippers. Nano Lett (2014) 0.82
The expression pattern of PFKFB3 enzyme distinguishes between induced-pluripotent stem cells and cancer stem cells. Oncotarget (2015) 0.81
Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment. Biomed Res Int (2015) 0.81
Exosomes enriched in stemness/metastatic-related mRNAS promote oncogenic potential in breast cancer. Oncotarget (2015) 0.81
Small nucleolar RNA 78 promotes the tumorigenesis in non-small cell lung cancer. J Exp Clin Cancer Res (2015) 0.81
Stochasticity in plant cellular growth and patterning. Front Plant Sci (2014) 0.80
Gene expression signatures of breast cancer stem and progenitor cells do not exhibit features of Warburg metabolism. Stem Cell Res Ther (2015) 0.79
The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms. Oncogene (2016) 0.78
Toward precision medicine of breast cancer. Theor Biol Med Model (2016) 0.77
Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation. Am J Cancer Res (2016) 0.77
Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors. Oncogene (2015) 0.77
Targeting the epigenetics of the DNA damage response in breast cancer. Cell Death Dis (2016) 0.76
Quantitative non-invasive cell characterisation and discrimination based on multispectral autofluorescence features. Sci Rep (2016) 0.75
Resistin potentiates chemoresistance and stemness of breast cancer cells: Implications for racially disparate therapeutic outcomes. Cancer Lett (2017) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
The clonal evolution of tumor cell populations. Science (1976) 24.39
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
Heterogeneity in breast cancer. J Clin Invest (2011) 2.86
The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol (2012) 2.83
Cancer stem cells: the challenges ahead. Nat Cell Biol (2013) 2.78
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol (2012) 2.56
Understanding cancer stem cell heterogeneity and plasticity. Cell Res (2012) 2.39
Targeted therapies for breast cancer. J Clin Invest (2011) 2.22
The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res (2011) 2.22
Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res (2012) 1.58
A new genome-driven integrated classification of breast cancer and its implications. EMBO J (2013) 1.47
Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer (2012) 1.21
Stem cells in breast tumours: are they ready for the clinic? Eur J Cancer (2012) 1.00
Breast cancer heterogeneity: mechanisms, proofs, and implications. J Cancer (2010) 0.99
Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res (2013) 0.98
Profiling of normal and malignant breast tissue show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers. BMC Cancer (2013) 0.97
Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients. Expert Rev Proteomics (2009) 0.96
Progress in breast cancer research. Proc Natl Acad Sci U S A (2012) 0.82
Deciphering the single-cell omic: innovative application for translational medicine. Expert Rev Proteomics (2012) 0.81